{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "HIMS",
  "name": "Hims & Hers Health, Inc.",
  "url": "https://orbyd.app/dossiers/HIMS/",
  "json_url": "https://orbyd.app/dossiers/HIMS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "GLP-1 reaccel gets marked to market on 2026-08-10: guide $680-700M (+25-28%) vs Q1's +4%, street at $698.9M. Since the last note the FTC/CA/UT sued (2026-07-29, N.D. Cal.), BofA cut $37 to $30, and Amazon ($50/mo Medicare GLP-1, 2026-08-06) plus CVS entered the lane. Consensus PT $30.32 now sits under the $31.59 close.",
  "invalidation_trigger": "A weekly close below $29 loses the $29.53 convertible conversion reference and the pre-print shelf; secondary condition: the 2026-08-10 Q2 print coming in under the $680M guide floor or a Q3 guide that fails to hold a +25% run-rate.",
  "catalyst_date": "2026-08-10",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "FTC, California and Utah complaint filed 2026-07-29 in N.D. Cal. Is unresolved; no hearing or response date has been disclosed as of 2026-08-07.",
    "$350M convertible notes priced May 2026 convert near $29.53 (32.5% premium to a $22.29 reference) - a standing dilution reference close to the tape.",
    "CFO David Wells bought 48,400 shares at $24.23 (~$1.17M) open-market, Form 4 dated 2026-05-27 - the only marked insider level in the record.",
    "Eucalyptus (~$1.15B; Australia, UK, Germany, Japan, Canada) is being integrated; BofA has argued international runs near breakeven for a multi-year period, a standing consolidated-margin drag.",
    "Retail-flow sensitive: unusual-options and whale flags recurred 2026-06-29, 2026-07-06 and 2026-07-08; intraday moves can be flow-driven rather than news-driven."
  ],
  "body_markdown": "## Current Thesis\nThe guide is $680–700M, +25–28% YoY against Q1's $608M and +4%; the street sits at $698.9M revenue and −$0.05 EPS versus +$0.17 a year ago (TipRanks preview). Three things have moved against the frame since the 2026-07-12 note. The FTC, joined by California and Utah, sued in the Northern District of California on 2026-07-29 over health-data sharing with Meta and Snap ad platforms plus undisclosed prescription charges and cancellation friction. The price-target chase reversed — BofA, which raised twice in nine days to $37 on 2026-07-09, has since been marked down to $30 (per analyst-rating aggregators, late July), and the TipRanks consensus target of $30.32 now sits under the $31.59 close of 2026-08-07. And distribution competition arrived on a weekly cadence: Amazon Pharmacy began delivering GLP-1s to eligible Medicare patients at $50/month on 2026-08-06, CVS retooled its weight-management program on 2026-08-05, DarioHealth announced a GLP-1 program on 2026-07-30.\n\n## Bull Case\n- **The guided inflection is specific and near:** Q2 $680–700M (+25–28% YoY) off a $608M/+4% Q1; FY $2.8–3.0B with adj. EBITDA $275–350M, issued with the Q1 print in May 2026. One report settles whether the trough was one quarter or a trend.\n- **The EPS bar is already negative:** consensus −$0.05 against +$0.17 in the year-ago quarter (TipRanks preview). Expectations on profitability have been reset downward ahead of the print; the top line carries the burden.\n- **Operational basis for the ramp:** 125,000+ branded Wegovy shipments in the first six weeks post-launch and roughly 100k+ new weight-loss subscribers per month, per the Q1 2026 call (May 2026).\n- **Marked insider level:** CFO David Wells bought 48,400 shares at $24.23 (~$1.17M) in the open market, Form 4 dated 2026-05-27.\n- **Funded international platform:** the ~$1.15B Eucalyptus acquisition (Australia, UK, Germany, Japan, Canada) closed, backed by the upsized $350M convertible priced in May 2026.\n- **Tape absorbed the legal headline:** the FTC complaint hit 2026-07-29 and shares rebounded on 2026-07-31; the three-month return through 2026-08-07 is +11.7%.\n- **Product cadence continues:** an AI care experience launched 2026-08-06, debuting with Hers Weight Loss members. No revenue contribution has been quantified.\n\n## Bear Case\n- **A federal enforcement action with two state AGs attached:** filed 2026-07-29 (N.D. Cal.), alleging pixel trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X carried user actions off-site, plus inadequate disclosure of prescription charges and obstructed cancellation. The subscription-mechanics counts go at the machinery that produces recurring revenue, not at a marketing line. The company called the allegations baseless on 2026-07-29 and said the FTC disregarded evidence supplied across a nearly three-year investigation.\n- **Distribution is being commoditized by scaled incumbents:** Amazon at $50/month for eligible Medicare patients (2026-08-06), CVS's program retool (2026-08-05) on top of its $49 MinuteClinic virtual visit (2026-06-22) and Zepbound coverage (2026-05-28), plus DarioHealth entering (2026-07-30).\n- **The sell-side re-rating fuel is spent and reversing:** Barclays $39 (2026-06-18) and Canaccord $40 (2026-07-01) remain the highs, but BofA's $37 (2026-07-09) has been cut to $30, and the consensus target of $30.32 with a 4 Buy / 8 Hold split sits below spot.\n- **The quarter before the promise was a miss:** Q1 2026 revenue $608M against $616–619M estimates, with roughly $33M of restructuring tied to exiting compounded semaglutide.\n- **Mechanical overhead near the tape:** the $350M convertible converts around $29.53, struck at a 32.5% premium to a $22.29 reference.\n- **The second narrative leg was capped in July:** an analyst flagged the FDA recommendation against adding seven peptides to the bulk list as a limit on the peptide/longevity optionality (2026-07-01).\n\n## Setup & Price Structure\nLast completed daily close $31.59 on 2026-08-07, 49.7% below the $62.76 52-week high, with RSI(14) at 47.8. Mid-range momentum into a binary print — no thrust, no washout. The $29.53 convertible conversion reference sits immediately beneath spot and is the nearest mechanical level; the $24.23 CFO purchase from 2026-05-27 is the deeper marked floor that held the spring repair.\n\nNarrative life-cycle: **SATURATED**. The dating is the last ten days. Coverage went fully mainstream on the FTC filing (NPR, CBS News, TechCrunch, Reuters, 2026-07-30). Three competitors announced into the same lane inside eight days (2026-07-30, 2026-08-05, 2026-08-06). And the street's own average target no longer clears the price — $30.32 versus a $31.59 close. That combination of general-audience coverage, incumbent entry and targets at or under spot is late-cycle, and it is a change from the MATURING read carried on 2026-07-12.\n\nCrowding and positioning observables, stated as observables: retail-sentiment coverage is clustering around the print (TipRanks published a retail-sentiment piece on HIMS ahead of Q2 earnings); unusual-options and whale flags recurred on 2026-06-29, 2026-07-06 and 2026-07-08; the earnings date is 2026-08-10, two sessions from the price basis; and the $350M convertible sits ~$29.53 as issuance-linked supply near spot. There is no insider selling in the recent record to point at — the only marked insider action is the May purchase.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-10 (confirmed, after close; call 5:00 pm ET)** — Q2 2026 results. Resolves the $680–700M guide against a $698.9M consensus that sits at the top of the band.\n- **2026-08-10 (same call)** — Q3 2026 guidance and the FY $2.8–3.0B / $275–350M adj. EBITDA framework. Whether the reaccel is a quarter or a run-rate is answered here, not in the Q2 number alone.\n- **~2026-08-12 (est.)** — Q2 10-Q filing. First written contingency language on the FTC action, and the first look at diluted share count against the $29.53 conversion reference.\n\n## Elapsed catalysts\n\n- **2026-07-29 (filed; no hearing or response date disclosed as of 2026-08-07)** — FTC / California / Utah action, N.D. Cal. Docket milestones are unscheduled, so this is an open-ended overhang rather than a dated event. *(passed 2d ago)*\n\n## What Would Change Our Mind\nThe cleanest break is arithmetic on 2026-08-10: revenue below the $680M floor of the company's own guide, or a Q3 guide that fails to hold a +25% run-rate, retires the inflection story outright and leaves a business growing in single digits while three scaled incumbents price against it. A second break is legal: a disclosed reserve or a consent order that forces changes to sign-up and cancellation flow would attack subscriber economics directly, and the Q2 10-Q is where that language first appears.\n\nIn price terms, a weekly close below $29 loses the $29.53 convertible conversion reference and the pre-print shelf; a subsequent loss of the $24.23 insider-purchase level would break the entire spring repair structure.\n\nThe case strengthens on the opposite set: Q2 revenue at or above the $698.9M consensus, the FY $2.8–3.0B band raised rather than reaffirmed, adj. EBITDA tracking inside $275–350M, and a subscriber add that holds the ~100k/month weight-loss pace described on the Q1 call. A ratings upgrade, rather than another target bump, would be the evidence that the sell-side is re-engaging, since targets are already at spot.\n\n## Correlation Notes\n- **GLP-1 supply complex:** the branded Wegovy ramp ties the story to Novo Nordisk's supply and pricing decisions; Eli Lilly's Medicare GLP-1 bridge program from 2026-07-01 (announced 2026-06-25) sets the competing access path.\n- **Retail-distribution read-across:** Amazon and CVS announcements now move this name's narrative directly, as seen 2026-08-05 and 2026-08-06.\n- **Regulatory read-across:** the 2026-07-29 FTC theory — ad pixels on health-related pages — applies to any consumer-health platform running third-party trackers, so a settlement here sets a template others get priced against.\n- **Flow beta over sector beta:** the whale/unusual-options clustering of late June and early July means intraday behaviour tracks retail options flow more than healthcare-services indices.\n- **Low AI-capex linkage:** despite the 2026-08-06 AI care launch, this is a consumer-health subscription business; it does not trade with the semiconductor or data-centre complex.",
  "first_seen": "2026-05-12",
  "last_analyzed": "2026-08-08T15:39:38+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}